Arrowhead reports FY2026 results, highlights REDEMPLO growth and sNDA submission
Arrowhead posted fiscal 2026 results on Nov. 12, 2026, detailing REDEMPLO prescription growth, an sNDA submission for plozasiran in severe hypertriglyceridemia, and new RNAi pipeline data.
SEC filing